Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in MOGAD
2021-003192-34Phase 3Active
- Sponsor
- Roche
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) comparing Satralizumab with Placebo (2 arms). Primary endpoint: Time from randomization to first adjudicated MOGAD relapse. Started Oct 2021; status: active.
02
Drugs
satralizumab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on 2021-003192-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003192-34.